OBI-992 (TROP2 ADC)

OBI-992 is a TROP2-directed antibody-drug-conjugate (ADC) that carries a potent topoisomerase I inhibitor. TROP2 is highly expressed in a variety of solid tumors such as lung, breast, ovarian, and gastric cancer, rendering it an ideal target for cancer therapy.

OBI-992 uses a hydrophilic, enzyme-cleavable linker that is stable in circulation but releases the cytotoxic payload inside tumor cells. OBI-992 demonstrates remarkable antitumor efficacy, improved pharmacokinetic characteristics, and a favorable safety profile in animal models.

The TROP-2 targeting antibody was in-licensed from Biosion Pharma in Dec 2021. OBI owns ex-China right of OBI-992. U.S. FDA cleared an IND application for a Phase 1/2 Study of OBI-992 on Jan, 2024.